TTOO
T2 Biosystems, Inc.0.0130
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
364.59KP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
8-K
Leadership overhaul at T2
T2 Biosystems saw mass resignations: directors John Sperzel, Robin Toft, and others quit March 31-April 3, 2025; CEO Sperzel, SVP Gibbs, and CFO Sprague also departed. Board swiftly named turnaround specialist Craig Jalbert as new CEO, President, Treasurer, and Secretary at $50,000/year, plus sole Class I director. Leadership gutted. Distress expertise signals wind-down mode.
8-K
Mass layoffs, execs to consultants
T2 Biosystems executed a drastic reduction-in-force on February 13, 2025, cutting substantially all employees and terminating CEO John Sperzel, CFO John Sprague, and General Counsel Michael Gibbs without cause—only to reappoint them immediately as consultants at reduced hourly rates. This follows Nasdaq's February 10 delisting notice, prompting cancellation of a March 3 special meeting and reverse stock split plan. Expect ~$1.0M in Q1 severance costs. Leadership stays intact, but thinly.
8-K
Nasdaq delists TTOO stock
Nasdaq's Hearings Panel ruled to delist T2 Biosystems' common stock on February 10, 2025, due to violations of the Bid Price Rule and MVLS Rule; trading suspends February 12. Shares shift to OTC Markets under TTOO, with OTCQX application planned. No appeal forthcoming. OTC trading risks liquidity constraints.
8-K
Loan amendment extends maturity
T2 Biosystems signed Amendment No. 12 to its term loan on January 16, 2025, waiving defaults while allowing interest to accrue in-kind until maturity. It hikes the final fee to 14% and pushes the interest-only period and maturity to March 31, 2026. Lenders get more skin in the game. This buys three months' breathing room amid funding pressures.
IPO
Employees
Sector
Industry
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
MEHCQ
CHROME HLDG CO
3.50+0.00
NEO
NeoGenomics, Inc.
11.67-0.25
PRPO
Precipio, Inc.
24.02-0.04
TMO
Thermo Fisher Scientific Inc
570.16-5.75
TWST
Twist Bioscience Corporation
31.13+0.06
WGS
GeneDx Holdings Corp.
141.72-8.89